Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, wound care products company Derma Sciences(NASDAQ:DSCI) has received a distressing one-star ranking.
With that in mind, let's take a closer look at Derma Sciences and see what CAPS investors are saying about the stock right now.
Derma Sciences facts
Princeton, N.J. (since 1984)
Health care supplies
Chairman/CEO Edward Quilty
Trailing-12-Month Return on Equity
$18.8 million / $0
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 8% of the 13 members who have rated Derma Sciences believe the stock will underperform the S&P 500 going forward.
They still lose money every quarter, there's no upward trend in revenues, and they seem to drag out their pipeline development endlessly. The company is now saying they will "begin their phase III program" for DSC127 for diabetic foot ulcers in 12/12. ...
When it finally really does begin, the phase III trial will compare DSC127 with placebo, and there's a good chance of showing stat sig benefit. That won't necessarily translate into commercial viability, however, as there are already many wound treatments for diabetic foot ulcers that do better than placebo. ... I expect significantly more dilution to take place before we see any phase III results for DSC127.
If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article 1-Star Stocks Poised to Plunge: Derma Sciences? originally appeared on Fool.com.
Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Covidien Ltd. and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.